SLC5A2 and type 2 diabetes mellitus: Canagliflozin was the first of four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) authorized by the food and drug administration (FDA) to reduce blood glucose levels in persons with T2DM when combined with diet and exercise [52].